OncoZenge AB (OSTO:ONCOZ) Net Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ONCOZ OncoZenge AB OSTO:ONCOZ
26 GF Score
Price kr7.49
! 2 Warning Signs
View Full Analysis

What is OncoZenge AB Net Margin %?

OncoZenge AB OSTO:ONCOZ +4.03% 26 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates OSTO:ONCOZ with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, OncoZenge AB ranks worse than 106157.01% on this metric.

Net margin is calculated as Net Income divided by its Revenue. OncoZenge AB's Net Income for the three months ended in Mar. 2026 was kr-7.13 Mil. OncoZenge AB's Revenue for the three months ended in Mar. 2026 was kr0.00 Mil. Therefore, OncoZenge AB's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for OncoZenge AB's Net Margin % or its related term are showing as below:


OSTO:ONCOZ's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

OncoZenge AB  (OSTO:ONCOZ) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

OncoZenge AB Net Margin % Related Terms

OncoZenge AB Net Margin % Historical Data

* Premium members only.

The historical data trend for OncoZenge AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoZenge AB Net Margin % Chart

OncoZenge AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -598.35

OncoZenge AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.62 0.00 0.00 0.00 0.00

OSTO:ONCOZ vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, OncoZenge AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoZenge AB Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's Net Margin % falls into.


OSTO:ONCOZ
26GF Score
OncoZenge AB OSTO:ONCOZ
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoZenge AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

OncoZenge AB's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-15.94/2.664
=-598.35 %

OncoZenge AB's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-7.132/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
OncoZenge AB (OSTO:ONCOZ) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on OncoZenge AB and its competitors. According to the industry distribution chart, OncoZenge AB ranks #999999 out of 942 companies in the Biotechnology industry.
Is OncoZenge AB's Net Margin % too high?
OncoZenge AB's current Net Margin % is 0.00%. Based on the distribution chart, OncoZenge AB ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OncoZenge AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does OncoZenge AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoZenge AB ranks #999999 out of 942 companies for Net Margin %. This places OncoZenge AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on OncoZenge AB and its competitors. OncoZenge AB's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoZenge AB stock overvalued right now?
OncoZenge AB (OSTO:ONCOZ) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. OncoZenge AB's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For OncoZenge AB (OSTO:ONCOZ), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoZenge AB Business Description

Address Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
26GF Score

Get the complete analysis for OSTO:ONCOZ

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr7.49
Price